Skip navigation

Epidermolysis Bullosa (EB)

BERG is committed to making a difference in the lives of patients and families dealing with the devastating effects of Epidermolysis Bullosa (EB).

EB is a rare, connective tissue disorder with many genetic and symptomatic variations characterized by extremely fragile skin and the development of recurrent, painful blisters, open sores, disfiguring scars, disabling musculoskeletal deformities, internal complications, and shortened life-span. Research indicates that one in every 20,000 children in the U.S. is born with the disease. There is currently no known EB cure or treatment.

BERG’s EB Drug Candidate (BPM 31510) Received FDA Orphan-Drug Designation in May 2018

BPM 31510 is a novel molecule that specially targets the mitochondria to influence the metabolism of cells. The effect of BPM 31510 on metabolism results in the normalization/reactivation of pathways that detect cellular dysfunction and damage – shifting biology towards normal.

  • Preclinical data demonstrates that BPM 31510 influences several components of wound healing pathways to help in the treatment of wounds.
  • BPM 31510 is currently in Phase 1 clinical investigation focused on establishing safety in wounds of patients with EB
  • Preliminary evidence suggests BPM 31510 appears to be well tolerated and also potentially efficacious in improving wound healing

EB Specific Treatment: BPM 31510 is in clinical development specifically for wound healing management in all types of EB patients.


Effective and Safe: BPM 31510 acts on the three stages of the wound healing cascade: inflammation, proliferation & remodeling. BPM 31510 has a favorable tolerability profile, as CoQ-10 is a molecule produced naturally in the human body.


Wound Healing Treatment: In the remodeling phases of the wound healing cascade, BPM 31510 influences the expression of structural proteins to potentially strengthen the skin.


Patient Friendly: BPM 31510 is a topical treatment that can be easily applied. The application is painless and comfortable.


BERG & debra of America


BERG has partnered with debra of America to support and advocate on behalf of patients and families affected by EB. debra of America is a non-profit organization that provides comprehensive support to those with epidermolysis bullosa (EB). It is the only national organization in the United States to offer free programs and services to affected individuals and their caregivers and fund research for an EB cure and treatment. By joining forces, we hope to galvanize the disease community and advance treatment research further.

The partnership creates a platform to elevate the EB disease profile by highlighting the potential EB treatments like BPM 31510 at key EB clinical conferences, strengthen EB patient advocacy efforts with Congress, and collaborate with top scientific investigators around the world. To learn more about the partnership, please click here.

In October 2017, BERG was honored to be recognized as a Partner in Progress from debra of America.

“As a father of a ten-year-old with a severe form of Epidermolysis Bullosa, and as Executive Director, I want to thank BERG for advancing necessary treatment options for the 25,000 people living in the United States with EB and the nearly 200 children born each year with the disease. debra of America is proud to honor BERG with our Partners in Progress Award for their pioneering approach to drug development and their commitment to improving the quality of life for EB patients and their families.”

– Brett Kopelan, Executive Director of debra of America.

To read more, please click here.

Clinical Trial

The phase 1 study for BPM 31510 for the treatment of EB is completed.

For more information about the trial, please click here.